Your activity: 291 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email:

Vitamin B1 (thiamine): Drug information

Vitamin B1 (thiamine): Drug information
(For additional information see "Vitamin B1 (thiamine): Patient drug information" and see "Vitamin B1 (thiamine): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: Canada
  • Thiamiject;
  • Vitamin B1
Pharmacologic Category
  • Vitamin, Water Soluble
Dosing: Adult
Beriberi treatment

Beriberi treatment:

Initial: IM, IV (preferred routes if critically ill), Oral: 100 to 200 mg 3 times daily for 2 to 3 days, followed by maintenance therapy (Ref).

Maintenance: Oral: 5 to 100 mg once daily until no longer at risk for deficiency (Ref). Note: Doses lower than 100 mg may be obtained in a multivitamin formulation.

Ethylene glycol poisoning

Ethylene glycol poisoning (adjunctive agent) (off-label use):

Note: For use as an adjunct to antidote therapy (Ref).

IV: 100 mg as a one-time dose (Ref).

Thiamine supplementation, including prevention of Wernicke encephalopathy

Thiamine supplementation, including prevention of Wernicke encephalopathy:

Note: Patients at high risk for developing thiamine deficiency include those with alcohol use disorder, GI disease and/or surgery (including bariatric surgery), hyperemesis gravidarum, or malignancy (Ref).

Wernicke encephalopathy, prevention, including those with alcohol withdrawal syndrome (off label): IV (preferred route), Oral, IM: 100 to 200 mg once daily for 3 to 5 days (Ref). Note: Administration prior to dextrose is recommended when feasible (Ref). Higher doses are used in patients for treatment of suspected or confirmed Wernicke encephalopathy (see “Wernicke Encephalopathy Treatment”).

Bariatric surgery, postoperative (off label): Oral: 12 to 100 mg/day in 1 or 2 divided doses; continue indefinitely. Note: Doses lower than 100 mg may be obtained in a multivitamin formulation (Ref).

Parenteral nutrition supplementation: IV: 6 mg/day (Ref).

Wernicke encephalopathy treatment

Wernicke encephalopathy treatment:

Initial: Note: Oral administration should not be used for initial treatment (Ref).

IV (preferred route), IM: 200 to 500 mg 3 times daily for 2 to 7 days, followed by 250 mg once daily for an additional 3 to 5 days, followed by maintenance therapy (Ref). Note: Administration prior to dextrose is recommended when feasible (Ref).

Maintenance: Oral: 100 mg daily until no longer at risk for deficiency (Ref).

Dosing: Kidney Impairment: Adult

No dosage adjustment provided in manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

No dosage adjustment provided in manufacturer's labeling.

Dosing: Pediatric

(For additional information see "Vitamin B1 (thiamine): Pediatric drug information")

Note: Dosing presented in mcg/kg, mg/kg, and mg/day; use precaution.

Parenteral nutrition, maintenance requirement

Parenteral nutrition, maintenance requirement (Ref): Limited data available: IV:

Infants: 0.35 to 0.5 mg/kg/day; maximum daily dose: 1.2 mg/day.

Children: 1.2 mg/day.

Thiamine deficiency; treatment

Thiamine deficiency (beriberi); treatment (critically ill):

Infants: Various regimens reported: Initial: IV: 25 to 50 mg once, followed by 10 mg IM once daily for a week then 3 to 5 mg orally once daily for at least 6 weeks (Ref). Other regimens with higher initial doses have also been reported. One study used an oral dose of 100 mg/day given as 25 mg, 25 mg, and 50 mg doses administered 30 minutes apart for 3 days (Ref). Another study administered 30 mg orally once daily for 20 days (Ref). Note: If patient is being breast-fed, the mother should also be considered for thiamine deficiency treatment (Ref).

Children: Limited data available: IM, IV: 10 mg once daily for the first week (if critically ill), then 3 to 5 mg orally once daily for at least 6 weeks (Ref).

Adolescents: Limited data available: IM, IV: 100 mg once daily for up to 7 days (if critically ill), then 10 mg orally once daily. Dosing based on several case reports (n=3, age 14 to 17 years) of beriberi treatment after gastric bypass surgery (Ref).

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral, as hydrochloride:

Generic: 50 mg

Solution, Injection, as hydrochloride:

Generic: 100 mg/mL (2 mL)

Solution, Injection, as hydrochloride [preservative free]:

Generic: 100 mg/mL (2 mL)

Tablet, Oral, as hydrochloride:

Generic: 50 mg, 100 mg, 250 mg

Tablet, Oral, as hydrochloride [preservative free]:

Generic: 100 mg

Tablet, Oral, as mononitrate:

Generic: 100 mg

Tablet, Oral, as mononitrate [preservative free]:

Generic: 100 mg

Generic Equivalent Available: US


Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection, as hydrochloride:

Thiamiject: 100 mg/mL (1 mL, 10 mL)

Generic: 100 mg/mL (1 mL, 10 mL)

Administration: Adult

IM, IV: Parenteral form may be administered by IM or IV injection. Various rates of IV administration have been reported; an extended infusion time (eg, over 15 to 30 minutes) has been suggested for doses ≥100 mg, although doses up to 250 mg have been safely administered via IV push (over 1 to 2 minutes) (Ref). If thiamine and nutrition support with parenteral carbohydrates (eg, glucose, dextrose) are both indicated, thiamine should be administered prior to parenteral carbohydrate solutions to prevent precipitation of acute symptoms of thiamine deficiency when feasible (Ref).

Administration: Pediatric

Oral: May administer with or without food (Ref).

Parenteral: May be administered by IM or IV injection. For IV administration, various rates of administration have been reported (eg, 100 mg over 5 minutes in adults). An extended infusion time is preferred for doses ≥100 mg. Local injection reactions may be minimized by slow administration (~30 minutes) into larger, more proximal veins. Thiamine should be administered prior to parenteral glucose solutions to prevent precipitation of acute symptoms of thiamine deficiency in the poorly nourished.

Use: Labeled Indications

Treatment of thiamine deficiency (including thiamine deficiency in pregnancy associated with neuropathy), beriberi (dry or wet variety), Wernicke encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or marginal thiamine status in individuals receiving IV dextrose; dietary supplement.

Use: Off-Label: Adult

Ethylene glycol poisoning; Thiamine supplementation, including prevention of Wernicke encephalopathy

Medication Safety Issues
Sound-alike/look-alike issues:

Thiamine may be confused with Tenormin, Thalomid, Thorazine

International issues:

Doxal [Brazil] may be confused with Doxil brand name for doxorubicin [US]

Doxal: Brand name for pyridoxine/thiamine [Brazil], but also the brand name for doxepin [Finland]

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with injection. Frequency not defined.

Central nervous system: Flushing sensation, restlessness

Dermatologic: Diaphoresis, pruritus, skin sclerosis (at the injection site following IM administration), urticaria

Gastrointestinal: Nausea

Hematologic & oncologic: Hemorrhage (into the gastrointestinal tract)

Hypersensitivity: Anaphylaxis (following IV administration), angioedema, hypersensitivity reaction (following IV administration)

Local: Tenderness at injection site (following IM administration)

Neuromuscular & skeletal: Weakness

Respiratory: Cyanosis, pharyngeal edema, pulmonary edema


Hypersensitivity to thiamine or any component of the formulation


Concerns related to adverse effects:

• Hypersensitivity reactions: Have been reported following repeated parenteral doses; consider skin test in individuals with history of allergic reactions.

Concurrent drug therapy issues:

• Dextrose: Administration of dextrose may precipitate acute symptoms of thiamine deficiency; use caution when thiamine status is marginal or suspect.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002).

Other warnings/precautions:

• Parenteral administration: Use with caution with parenteral route (especially IV) of administration.

• Vitamin deficiency: Single vitamin deficiency is rare; evaluate for other deficiencies.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Etamsylate: May diminish the therapeutic effect of Thiamine. Management: If a patient is to receive intravenous (IV) etamsylate and an IV infusion containing thiamine, administer etamsylate first to avoid thiamine degradation by sulfites contained in the etamsylate product. Risk D: Consider therapy modification

Food Interactions

Food: High carbohydrate diets may increase thiamine requirement.

Pregnancy Considerations

Water soluble vitamins cross the placenta. Thiamine requirements are increased in during pregnancy (IOM 1998).

Pregnant females are at increased risk of thiamine deficiency when prolonged nausea and vomiting (including hyperemesis gravidarum) occurs; deficiency may present as a polyneuropathy or Wernicke encephalopathy (Chiossi 2006; Karjalainen 1965; WHO 1999).

Thiamine supplementation is recommended in pregnant females with prolonged vomiting. Initial treatment with IV thiamine is needed when Wernicke encephalopathy is suspected. Oral, IM, or IV therapy may be considered depending on severity of thiamine deficiency (Berdai 2016; Chiossi 2006; Palacios-Marqués 2012). When intravenous hydration is used in the management of hyperemesis gravidarum, thiamine should be administered prior to infusing dextrose to prevent Wernicke encephalopathy (ACOG 189 2018).

Breastfeeding Considerations

Thiamine is present in breast milk (IOM 1998).

Thiamine concentrations in breast milk are similar in well-nourished mothers who use supplements and those that do not (IOM 1998).

Thiamine requirements are increased in breastfeeding females (IOM 1998). Females with a thiamine deficiency may lead to a deficiency in exclusively breastfed infants (Barennes 2015; Coats 2012). When a deficiency is present, supplementation of both the mother and infant is recommended (WHO 1999)

Dietary Considerations

Dietary sources include legumes, pork, beef, whole grains, yeast, and fresh vegetables. A deficiency state can occur in as little as 3 weeks following total dietary absence.

Dietary reference intake (IOM 1998):

0 to 6 months: Adequate intake: 0.2 mg/day

7 to 12 months: Adequate intake: 0.3 mg/day

1 to 3 years: RDA: 0.5 mg

4 to 8 years: RDA: 0.6 mg

9 to 13 years: RDA: 0.9 mg

14 to 18 years: RDA: Females: 1 mg; Males: 1.2 mg

≥19 years: RDA: Females: 1.1 mg; Males: 1.2 mg

Pregnancy, lactation: RDA: 1.4 mg

Reference Range

Normal, serum: 1.1-1.6 mg/dL

Mechanism of Action

An essential coenzyme in carbohydrate metabolism by combining with adenosine triphosphate to form thiamine pyrophosphate.

When used for the treatment of ethylene glycol poisoning, thiamine is theorized to increase the formation of glycine, a nontoxic metabolite.


Absorption: Oral: Adequate; IM: Rapid and complete

Distribution: Highest concentrations found in brain, heart, kidney, liver

Metabolism: In the liver

Excretion: Urine (as unchanged drug and as pyrimidine after body storage sites become saturated)

Pricing: US

Solution (Thiamine HCl Injection)

100 mg/mL (per mL): $3.94 - $5.97

Tablets (Thiamine HCl Oral)

100 mg (per each): $0.03 - $0.09

Tablets (Thiamine Mononitrate Oral)

100 mg (per each): $0.03 - $0.19

Tablets (Vitamin B-1 Oral)

100 mg (per each): $0.17 - $0.23

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Abery (JP);
  • Actamin (JP);
  • AFI-B (NO);
  • Aliaron D 10 (JP);
  • Anerex (MX);
  • Aneurin-AS (DE);
  • Arcavit-B1 (AT);
  • B1-ASmedic (DE);
  • B1-Vicotrat (DE);
  • Becaps (BR);
  • Benalgis (IN);
  • Benerva (AE, AR, BB, BE, BH, BM, BR, BS, BZ, CH, CY, EG, ES, FR, GB, GH, GR, GY, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LU, LY, NL, OM, PE, QA, SA, SE, SR, SY, TT, TZ, UG, YE, ZM);
  • Beneuran (AT);
  • Beneurol (LU);
  • Beneuron (IN);
  • Bermin B (JP);
  • Beta-Sol (AU);
  • Beta-Tabs (AU);
  • Betabion (DE);
  • Betamin (AU);
  • Betamine (LU);
  • Bevitine (FR);
  • Bevitol (AT);
  • Biogen (JP);
  • Bwerin (IN);
  • Dagravit B1 (PT);
  • Dexabion (MX);
  • Hiace (JP);
  • Hithia (JP);
  • Incremin con Hierro (MX);
  • Kirin B1 (JP);
  • Lophakomp-B1 (DE);
  • Metabolin (JP);
  • Mutsutamin (JP);
  • Neo-Panlacticos (MX);
  • Neuramin (FI);
  • Pagavit (MX);
  • Pharmaton (MX);
  • Plivit B1 (HR);
  • Strong Vita-B Injection (TW);
  • Suma-B (MX);
  • Thiamine Injection (AU);
  • Tiacur (NO);
  • Tiamidexal (MX);
  • Tiamin ”Dak” (DK);
  • Tiamina (CO);
  • Tiaminal (MX);
  • Tolima (DE);
  • Tribedoce (MX);
  • Trifosfaneurina (PT);
  • Tyvera (MT);
  • Vit. B1 Agepha (AT);
  • Vita-B1 (FI);
  • Vitamin B1 (HU);
  • Vitamin B1 Jenapharm (DE);
  • Vitamin B1 Kattwiga (DE);
  • Vitamin B1-Hevert (DE);
  • Vitamin B1-Injektopas (DE);
  • Vitamin B1-ratiopharm (DE);
  • Vitamina B1 Biol (AR);
  • Vitaminum B1 (PL);
  • Vitanon[inj.] (JP)

For country code abbreviations (show table)
  1. Aluminum in large and small volume parenterals used in total parenteral nutrition. Fed Regist. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.
  2. American College of Obstetricians and Gynecologists (ACOG). Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea and vomiting of pregnancy. Obstet Gynecol. 2018;131(1):15-30. doi:10.1097/AOG.0000000000002456 [PubMed 29266076]
  3. American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. Published November 2020.
  4. American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. J Addict Med. 2020:14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668 [PubMed 32511109]
  5. August D, Teitelbaum D, Albina J, et al. Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients: Section VII: Normal Requirements - Pediatrics. JPEN J Parenter Enteral Nutr. 2002;26(1):25-32.
  6. B-1 [prescribing information]. Miami Lakes, FL: Mason Vitamins; 2015.
  7. Barceloux DG, Krenzelok EP, Olson K, Watson W. American Academy of Clinical Toxicology practice guidelines on the treatment of ethylene glycol poisoning. J Toxicol Clin Toxicol. 1999;37(5):537-560. [PubMed 10497633]
  8. Barennes H, Sengkhamyong K, René JP, Phimmasane M. Beriberi (thiamine deficiency) and high infant mortality in northern Laos. PLoS Negl Trop Dis. 2015;9(3):e0003581. [PubMed 25781926]
  9. Berdai MA, Labib S, Harandou M. Wernicke's encephalopathy complicating hyperemesis during pregnancy. Case Rep Crit Care. 2016;2016:8783932. doi:10.1155/2016/8783932 [PubMed 26989522]
  10. Bowman BA, Pfeiffer CM, Barfield WD. Thiamine deficiency, beriberi, and maternal and child health: why pharmacokinetics matter. Am J Clin Nutr. 2013;98(3):635-636. [PubMed 23902781]
  11. Coats D, Shelton-Dodge K, Ou K, et al. Thiamine deficiency in Cambodian infants with and without beriberi. J Pediatr. 2012;161(5):843-847. [PubMed 22703952]
  12. Chiossi G, Neri I, Cavazzuti M, et al. Hyperemesis Gravidarum Complicated by Wernicke Encephalopathy: Background, Case Report, and Review of the Literature. Obstet Gynecol Surv. 2006;61(4):255-268. [PubMed 16551377]
  13. Flannery AH, Adkins DA, Cook AM. Unpeeling the evidence for the banana bag: evidence-based recommendations for the management of alcohol-associated vitamin and electrolyte deficiencies in the ICU. Crit Care Med. 2016;44(8):1545-1552. doi:10.1097/CCM.0000000000001659 [PubMed 27002274]
  14. Frank LL. Thiamin in clinical practice. JPEN J Parenter Enteral Nutr. 2015;39(5):503-520. doi:10.1177/0148607114565245 [PubMed 25564426]
  15. Fujii T, Luethi N, Young PJ, et al; VITAMINS Trial Investigators. Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial. JAMA. 2020;323(5):423-431. doi:10.1001/jama.2019.22176 [PubMed 31950979]
  16. Gahart BL, Nazareno AR, Ortega MQ. Gahart’s 2021 Intravenous Medications: A Handbook for Nurses and Health Professionals. 37th ed. Elsevier; 2021, 1270-1271.
  17. Galvin R, Bråthen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA; EFNS. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010;17(12):1408-1418. doi:10.1111/j.1468-1331.2010.03153.x [PubMed 20642790]
  18. Hoffman RS. Antidotes in depth: thiamine. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds. Goldfrank's Toxicologic Emergencies. 10th ed. McGraw-Hill Companies Inc; 2015.
  19. IOM (Institute of Medicine). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. National Academy Press; 1998.
  20. Karjalainen AO. Neurological disorders in pregnancy: multiple sclerosis, gestational polyneuritis and meningitis. Ann Chir Gynaecol Fenn. 1965;54(4):453‐461. [PubMed 5858086]
  21. Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson' s Textbook of Pediatrics. 20th ed. Saunders Elsevier; 2016.
  22. Kushner RF, Herron DM, Herrington H. Bariatric surgery: postoperative nutritional management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed October 21, 2022
  23. Latt N, Dore G. Thiamine in the treatment of Wernicke encephalopathy in patients with alcohol use disorders. Intern Med J. 2014;44(9):911‐915. doi:10.1111/imj.12522 [PubMed 25201422]
  24. Lei Y, Zheng MH, Huang W, Zhang J, Lu Y. Wet beriberi with multiple organ failure remarkably reversed by thiamine administration: a case report and literature review. Medicine (Baltimore). 2018;97(9):e0010. doi:10.1097/MD.0000000000010010 [PubMed 29489643]
  25. McLaughlin K, Joyal K, Lee S, et al. Safety of intravenous push thiamine administration at a tertiary academic medical center. J Am Pharm Assoc (2003). 2020;60(4):598-601. doi:10.1016/j.japh.2019.12.005 [PubMed 31932197]
  26. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  27. Moskowitz A, Huang DT, Hou PC, et al; ACTS Clinical Trial Investigators. Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial. JAMA. 2020;324(7):642-650. doi:10.1001/jama.2020.11946 [PubMed 32809003]
  28. Palacios-Marqués A, Delgado-García S, Martín-Bayón T, Martínez-Escoriza JC. Wernicke's encephalopathy induced by hyperemesis gravidarum. BMJ Case Rep. 2012;2012:bcr2012006216. doi:10.1136/bcr-2012-006216 [PubMed 22684836]
  29. Pazirandeh S. Overview of water-soluble vitamins. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed October 28, 2022.
  30. Schabelman E, Kuo D. Glucose before thiamine for Wernicke encephalopathy: a literature review. J Emerg Med. 2012;42(4):488-494. doi:10.1016/j.jemermed.2011.05.076 [PubMed 22104258]
  31. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455. [PubMed 17434099]
  32. Sevransky JE, Rothman RE, Hager DN, et al; VICTAS Investigators. Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial. JAMA. 2021;325(8):742-750. doi:10.1001/jama.2020.24505 [PubMed 33620405]
  33. So YT. Wernicke encephalopathy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed October 28, 2022.
  34. Sriram K, Manzanares W, Joseph K. Thiamine in nutrition therapy. Nutr Clin Pract. 2012;27(1):41-50. doi:10.1177/0884533611426149 [PubMed 22223666]
  35. Thiamine [prescribing information]. Lake Zurich, IL: Premier Inc; August 2015.
  36. Thomson AD, Cook CC, Touquet R, et al. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke's encephalopathy in the accident and emergency department. Alcohol Alcohol. 2002;37(6):513-521. [PubMed 12414541]
  37. Tjugum SL, Hedrick TL, Jean SJ, Heeney SA, Rohde KA, Campbell-Bright SL. Evaluation of the safety of intravenous thiamine administration in a large academic medical center. J Pharm Pract. 2019;897190019872584. doi:10.1177/0897190019872584 [PubMed 31495250]
  38. Towbin A, Inge TH, Garcia VF, et al. Beriberi after gastric bypass surgery in adolescence. J Pediatr. 2004;145(2):263-267. doi:10.1016/j.jpeds.2004.04.051 [PubMed 15289782]
  39. Van Haecke P, Ramaekers D, Vanderwegen L, et al. Thiamine-Induced Anaphylactic Shock. Am J Emerg Med. 1995;13(3):371-372. [PubMed 7755837]
  40. Vanek VW, Borum P, Buchman A, et al. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products. Nutr Clin Pract. 2012;27(4):440-491. [PubMed 22730042]
  41. World Health Organization (WHO). Thiamine deficiency and its prevention and control in major emergencies. 1999
  42. Yin H, Xu Q, Cao Y, Qi Y, Yu T, Lu W. Nonalcoholic Wernicke's encephalopathy: a retrospective study of 17 cases. J Int Med Res. 2019;47(10):4886‐4894. doi:10.1177/0300060519870951 [PubMed 31502510]
Topic 9988 Version 287.0